Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous infliximab with or without concomitant immunosuppression in moderate to severe Crohn’s disease
KCT0008431Phase 3Recruiting
- Sponsor
- Celltrion
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab in Crohn's disease, sponsored by Celltrion. Started Mar 2024; status: recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on KCT0008431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008431.